Journal of Antimicrobial Chemotherapy (2001) 48, 751-755
© 2001 The British Society for Antimicrobial Chemotherapy
Review |
Imiquimod and resiquimod as novel immunomodulators
a Departments of Infectious Diseases and c Genito-urinary Medicine, Royal Hallamshire Hospital, Sheffield; b Division of Genomic Medicine, F Floor, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Augmenting the host's natural immune response to viruses by the administration of exogenous cytokines such as interferon-
(IFN-) is a strategy increasingly employed in antiviral therapeutics. Enhancing the release of endogenous cytokines is, however, an alternative approach. The imidazoquinolinamines imiquimod and resiquimod have demonstrated potency as inducers of IFN- and other cytokines both in vitro and in vivo. Cytokine gene activation is mediated via the signal transducer and activator of transcription 1 (STAT-1) and involves the transcription factors NF
B and 4F1. Antiviral activity has been demonstrated against a variety of viruses, and clinical efficacy has been demonstrated against genital warts, herpes genitalis and molluscum contagiosum. Imiquimod is administered as a 5% cream (Aldara) and has been licensed for the treatment of anogenital warts in immunocompetent patients. Complete clearance of warts has been observed in up to half of treated patients with only local side effects reported. Resiquimod can be administered topically but also exists as an oral formulation. The range of potential infections for which these agents may have clinical utility includes chronic hepatitis C virus infection and Kaposi's sarcoma. In addition, the imidazoquinolinamines may find roles in the therapy of cancers and as vaccine adjuvants.
* Corresponding author. Tel: +44-114-271-2160; Fax: +44-114-273-9926; E-mail: d.h.dockrell{at}shef.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. L. Wynn, P. O. Scumpia, R. D. Winfield, M. J. Delano, K. Kelly-Scumpia, T. Barker, R. Ungaro, O. Levy, and L. L. Moldawer Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists Blood, September 1, 2008; 112(5): 1750 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Zagon, R. N. Donahue, M. Rogosnitzky, and P. J. Mclaughlin Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function Experimental Biology and Medicine, August 1, 2008; 233(8): 968 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hattermann, S. Picard, M. Borgeat, P. Leclerc, M. Pouliot, and P. Borgeat The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis FASEB J, May 1, 2007; 21(7): 1575 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Flacher, M. Bouschbacher, E. Verronese, C. Massacrier, V. Sisirak, O. Berthier-Vergnes, B. de Saint-Vis, C. Caux, C. Dezutter-Dambuyant, S. Lebecque, et al. Human Langerhans Cells Express a Specific TLR Profile and Differentially Respond to Viruses and Gram-Positive Bacteria J. Immunol., December 1, 2006; 177(11): 7959 - 7967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Razonable, M. Henault, H. L. Watson, and C. V. Paya Nystatin Induces Secretion of Interleukin (IL)-1{beta}, IL-8, and Tumor Necrosis Factor Alpha by a Toll-Like Receptor-Dependent Mechanism Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3546 - 3549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Caron, D. Duluc, I. Fremaux, P. Jeannin, C. David, H. Gascan, and Y. Delneste Direct Stimulation of Human T Cells via TLR5 and TLR7/8: Flagellin and R-848 Up-Regulate Proliferation and IFN-{gamma} Production by Memory CD4+ T Cells J. Immunol., August 1, 2005; 175(3): 1551 - 1557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nagase, S. Okugawa, Y. Ota, M. Yamaguchi, H. Tomizawa, K. Matsushima, K. Ohta, K. Yamamoto, and K. Hirai Expression and Function of Toll-Like Receptors in Eosinophils: Activation by Toll-Like Receptor 7 Ligand J. Immunol., October 15, 2003; 171(8): 3977 - 3982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Urosevic, T. Maier, B. Benninghoff, H. Slade, G. Burg, and R. Dummer Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo Arch Dermatol, October 1, 2003; 139(10): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|